Trials / Completed
CompletedNCT04224415
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
Re-challenge of Anti-EGFR Agents for Chinese Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Yuhong Li · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
Detailed description
After first-line treatment of FOLFOX/FOLFIRI/FOLFOXIRI plus Cetuximab failure and defined as RAS/BRAF wild-type by molecular detection of cycle tumor DNA, the patients will be treated with Cetuximab and Irinotecan as a second-line or third-line treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C225+CPT-11 | Patients will receive Systemic C225+CPT-11 every 14 days: C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1 |
Timeline
- Start date
- 2020-01-31
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2020-01-13
- Last updated
- 2023-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04224415. Inclusion in this directory is not an endorsement.